RecruitingPHASE1, PHASE2NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Studying Skeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Zilovertamab vedotin(biological)
- Enrollment
- 90 enrolled
- Eligibility
- 25 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles, California, United States
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado, United States
- Yale New Haven Hospital ( Site 1012), New Haven, Connecticut, United States
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg, Florida, United States
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa, United States
- Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts, United States
- Corewell Health ( Site 1001), Grand Rapids, Michigan, United States
- Children's Mercy Hospital ( Site 1024), Kansas City, Missouri, United States
- Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey, United States
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York, New York, United States
- New York Medical College ( Site 1023), Valhalla, New York, United States
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota, United States
- Oregon Health and Science University ( Site 1004), Portland, Oregon, United States
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania, United States
- Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06395103 on ClinicalTrials.govOther trials for Skeletal Ewing sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188532Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR TrialMayo Clinic
- RECRUITINGPHASE2NCT06699472A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibFudan University
- RECRUITINGPHASE2NCT05968768To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)Anna Raciborska
- RECRUITINGPHASE1NCT06156410Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasChildren's Hospital of Philadelphia